torcetrapib has been researched along with Coronary Disease in 16 studies
*Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, LP; Chang, M; Chen, AY; Chen, XQ; Cooper, CB; Finlay, HJ; Galella, MA; Harikrishnan, LS; Huang, CS; Jiang, J; Kamau, MG; Lawrence, RM; Li, J; Miller, AV; Nirschl, DS; Poss, MA; Qiao, JX; Salvati, ME; Sitkoff, DF; Sleph, PG; Taylor, DS; Van Kirk, K; Wang, TC; Wexler, RR; Yang, RZ; Yin, X | 1 |
| Amin, RP; Bao, J; Blaustein, RO; Campeau, LC; Chen, Q; Chen, YH; Cote, J; Duffy, JL; Hartmann, G; Johns, DG; Katipally, R; Leung, D; Lipardi, C; Liu, G; Liu, J; Lu, Z; Metzger, D; Mitra, K; Murphy, BA; Ondeyka, D; Shao, PP; Sinclair, PJ; Sun, W; Tan, L; Tyagarajan, S; Vachal, P; Wang, SP; Wollenberg, GK; Xu, Y; Ye, F; Zhao, K | 1 |
| Bis, JC; Charoen, P; Chaturvedi, N; Drenos, F; Finan, C; Franceschini, N; Gaunt, TR; Giambartolomei, C; Gordillo-Marañón, M; Hingorani, AD; Hughes, AD; Hunt, NB; Kivimaki, M; Lawlor, DA; Mook-Kanamori, DO; O'Donnell, CJ; Papacosta, O; Price, JF; Schmidt, AF; Sofat, R; Wannamethee, G; Wong, A; Zwierzyna, M | 1 |
| Schaefer, EJ | 1 |
| deGoma, EM; Rader, DJ | 1 |
| Francis, DP; Keene, D; Price, C; Shun-Shin, MJ | 1 |
| Tomlinson, B | 1 |
| Mombelli, G; Sirtori, CR | 1 |
| Toth, PP | 1 |
| Bays, H; Davidson, M; McKenney, J | 1 |
| Chapman, MJ | 1 |
| Asztalos, BF; Schaefer, EJ | 1 |
| Einecke, D | 1 |
| Hoekstra, JA; McKenney, JM | 1 |
| Barter, PJ; Brewer, B; Buhr, KA; Caulfield, M; Eriksson, M; Fisher, MR; Grundy, SM; Kastelein, JJ; Komajda, M; Lopez-Sendon, J; Mosca, L; Revkin, JH; Shear, CL; Tall, AR; Tardif, JC; Waters, DD | 1 |
| Ewart, RM | 1 |
9 review(s) available for torcetrapib and Coronary Disease
| Article | Year |
|---|---|
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Humans; Mendelian Randomization Analysis; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2021 |
Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Topics: Amides; Anticholesteremic Agents; Apolipoproteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Lipid Metabolism; Protein Binding; Quinolines; Sulfhydryl Compounds; Treatment Failure; Triglycerides | 2013 |
Future of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2014 |
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Myocardial Infarction; Niacin; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Stroke; Sulfhydryl Compounds | 2014 |
CETP Inhibition: does the future look promising?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Incidence; Male; Quinolines; Risk Factors | 2011 |
Torcetrapib/atorvastatin combination therapy.
Topics: Animals; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines | 2005 |
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Topics: Amides; Animals; Atherosclerosis; Biological Transport; Cholesterol; Cholesterol, HDL; Coronary Disease; Esters; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; PPAR alpha; PPAR delta; PPAR gamma; Quinolines; Sulfhydryl Compounds | 2006 |
Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
Topics: Amides; Animals; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Glycoproteins; Humans; Lipid Metabolism; Lipoproteins, HDL; Quinolines; Risk; Sulfhydryl Compounds | 2006 |
Will torcetrapib be the next big thing in coronary heart disease risk reduction?
Topics: Anticholesteremic Agents; Coronary Disease; Forecasting; Humans; Quinolines; Risk | 2007 |
1 trial(s) available for torcetrapib and Coronary Disease
| Article | Year |
|---|---|
Effects of torcetrapib in patients at high risk for coronary events.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mortality; Pyrroles; Quinolines | 2007 |
6 other study(ies) available for torcetrapib and Coronary Disease
| Article | Year |
|---|---|
Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-100; Blood Pressure; Cholesterol Ester Transfer Proteins; Coronary Disease; Cricetinae; Drug Discovery; Heart Rate; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Transgenic; Molecular Structure; Pyridines; Rats; Stilbenes | 2012 |
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Dogs; Humans; Macaca mulatta; Mice, Inbred C57BL; Molecular Structure; Oxazolidinones; Rats, Wistar; Structure-Activity Relationship | 2021 |
Raising high-density lipoprotein: for better or worse?
Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Disease; Humans; Quinolines | 2010 |
Cholesteryl ester transfer protein antagonism by drugs--a poor choice.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Polymorphism, Genetic; Pyrroles; Quinolines; Risk | 2010 |
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Lessons from torcetrapib: putting patient-oriented evidence first.
Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Disease; Humans; Hyperhomocysteinemia; Prognosis; Quinolines | 2008 |